Remarks

• Several other therapeutic options exist for patients with COVID-19 across the severity spectrum: see decision support tool for patients with non-severe COVID-19.
• The GDG considered in vitro data demonstrating that casirivimab-imdevimab does not neutralize the currently circulating variants of SARS-CoV-2 and their subvariants.
• There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab and casirivimab-imdevimab.
• However, there was also consensus regarding the need for clinical trial evidence in order to confirm any clinical effectiveness of new monoclonal antibodies that reliably neutralize the circulating strains in vitro.